Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ARD-501
- Development stage
- Phase 2
- Lead developer
- Artisan Therapeutics
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
ARD-501 is an oral liquid extended-release formulation of an existing, well-tolerated opioid receptor modulating drug. Initially developed by Aardvark Therapeutics, Inc., its development later involved a joint venture between Artisan Therapeutics, Inc. and Tulex Pharmaceuticals, Inc., under which it was also known as ART-501. It is currently in clinical development for the treatment of Autism Spectrum Disorder (ASD), where it has shown potential in improving ASD-related conditions.
- Brand names
- ART-501ART501ART 501
02
Targets
MOR (Mu opioid receptor)
Beyond the preview
Go deeper on ARD-501.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ARD-501.